Block listing Interim Review

RNS Number : 1744Y

AstraZeneca PLC

01 December 2017

 

1 December 2017 15:00 GMT

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.

Date: 1 December 2017

Name of applicant:		ASTRAZENECA PLC
Name of scheme:		ASTRAZENECA SHARE OPTION PLAN; ASTRAZENECA SAVINGS-RELATED SHARE OPTION PLAN; ASTRAZENECA ALL-EMPLOYEE SHARE PLAN; ASTRAZENECA PLC 2012 SAVINGS-RELATED SHARE OPTION SCHEME
Period of return:	From:	1 June 2017	To:	30 November 2017
Balance of unallotted securities under scheme(s) from previous return:		2,891,656
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		0
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):		234,464
Equals: Balance under scheme(s) not yet issued/allotted at end of period:		2,657,192

Name of contact:	CAMILLA WISEMAN
Telephone number of contact:	020 3749 5000

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. 

For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.

Media Relations
Esra Erkal-Paler	UK/Global	[phone]
Karen Birmingham	UK/Global	[phone]
Rob Skelding	UK/Global	[phone]
Matt Kent	UK/Global	[phone]
Gonzalo Viña	UK/Global	[phone]
Jacob Lund	Sweden	[phone]
Michele Meixell	US	[phone]
Investor Relations
Thomas Kudsk Larsen		[phone]
Craig Marks	Finance, Fixed Income, M&A	[phone]
Henry Wheeler	Oncology	[phone]
Mitchell Chan	Oncology; Other	[phone]
Christer Gruvris	Brilinta; Diabetes	[phone]
Nick Stone	Respiratory; Renal	[phone]
US toll free		[phone]

Adrian Kemp
Company Secretary

AstraZeneca PLC

 

END

 

 

BLRFSSFLFFWSESE